Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

To join this study, you need to be an adult (18 years or older) and weigh at least 40 kilograms (about 6 stone 4 pounds). You must have a clear diagnosis of EGPA that has been present for at least six months, and your EGPA must either keep coming back or not respond well to current treatments.

You also need to be taking a stable dose of a specific steroid medicine (prednisolone or prednisone, between 7.5mg and 50mg per day) for at least four weeks before the study starts. If you're on other immune-suppressing medicines (but not cyclophosphamide), their dose also needs to be stable. If you are a woman who could become pregnant, you'll need to be using a very reliable form of contraception.

There are some reasons you might not be able to join. For example, if you have a different but similar condition called Granulomatosis with Polyangiitis (Wegener's) or Microscopic Polyangiitis, you wouldn't be able to take part. Also, if your EGPA is severely affecting your organs in a life-threatening way, you would not be eligible for this study.

The specific details of what taking part involves, such as the total number of visits, how often you'll need to attend the clinic, and for how long, would be fully explained by the study team. You would likely have regular appointments for check-ups, blood tests, and other assessments to monitor your health and how the treatment is working. The study involves taking either Depemokimab, Mepolizumab, or a placebo (a dummy medicine) alongside your current EGPA treatment. You wouldn't know which one you're receiving. There would also be follow-up appointments after you finish taking the study medicine. The total duration of your participation, from your first visit to your last follow-up, would be clearly outlined before you decide to join.